


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHUANGMEI PHARMACEUTICAL CO., LTD.\***

### **創美藥業股份有限公司**

*(a joint stock limited liability company established in the People’s Republic of China)*

**(Stock Code: 2289)**

### **POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 3 JUNE 2016**

The Board is pleased to announce that all the resolutions as set out in the Notice of AGM were duly passed by the Shareholders by way of poll at the AGM.

References are made to the notice of the annual general meeting of Chuangmei Pharmaceutical Co., Ltd. (the “**Company**”) dated 18 April 2016 (the “**Notice of AGM**”) and the circular of the Company dated 18 April 2016 (the “**Circular**”). Terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

#### **POLL RESULTS OF THE AGM**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that all the proposed resolutions as set out in the Notice of AGM were duly passed by the shareholders of the Company (the “**Shareholders**”) by way of poll at the annual general meeting of the Company held on 3 June 2016 (the “**AGM**”).

\* *For identification purposes only*

The poll results in respect of all the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Shares Actually Voted (%)		
		For	Against	Abstain
1.	To consider and approve the report of the Board of Directors of the Company for the year ended 31 December 2015.	92,208,500 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the report of the supervisory committee of the Company for the year ended 31 December 2015.	92,208,500 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the report of the auditors and the audited consolidated financial statements of the Company for the year ended 31 December 2015.	92,208,500 (100%)	0 (0%)	0 (0%)
4.	To consider and approve the reappointment of SHINEWING (HK) CPA Limited as the auditor of the Company, to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration.	92,208,500 (100%)	0 (0%)	0 (0%)
5.	To authorise the Board to fix the remuneration of the Directors and Supervisors.	92,208,500 (100%)	0 (0%)	0 (0%)
6.	To consider and approve the Company of increasing the registered capital of its subsidiary Foshan Chuangmei Pharmaceutical Co., Ltd.* (佛山創美藥業有限公司) (“ <b>Foshan Chuangmei</b> ”) by RMB100 million.	92,208,500 (100%)	0 (0%)	0 (0%)
7.	To consider and approve granting to the Board an authorization to impose in its absolute discretion the relevant financing matters of the Company and its subsidiaries within the financing scope amounting to an addition of RMB500million (including but not limited to loans, facilities, trusts, and financing leases, etc).	92,208,500 (100%)	0 (0%)	0 (0%)
8.	To consider and approve granting to the Board an authorization to provide assistance (including but not limited to guarantees, credit supports, etc) in its absolute discretion to the financing matters of Foshan Chuangmei within the financing scope amounting to an addition of RMB400 million (including but not limited to loans, facilities, trusts, and financing leases, etc).	92,208,500 (100%)	0 (0%)	0 (0%)

Special Resolutions		Number of Shares Actually Voted (%)		
		For	Against	Abstain
9.	To give a general mandate to the Board to allot, issue and deal with additional domestic shares not exceeding 20% of the domestic shares of the Company in issue and additional H shares not exceeding 20% of the H Shares of the Company in issue and authorise the Board to make corresponding amendments to the articles of association of the Company (“ <b>Articles</b> ”) as it thinks fit so as to reflect the new capital structure upon the allotment or issuance of shares pursuant to such mandate.	92,208,500 (100%)	0 (0%)	0 (0%)
10.	To consider and approve adoption “Charmacy Pharmaceutical Co., Ltd.” as the English name of the Company (details of which are set out in the circular of the Company dated 18 April 2016), and that any Director be and is hereby authorized to do all such acts and things and execute all such documents which he/she consider necessary, desirable or expedient for the purposes of, or in connection with, the implementation of and giving effect to such adoption of the English name of the Company and to attend to any necessary filings for and on behalf of the Company.	92,208,500 (100%)	0 (0%)	0 (0%)
11.	To consider and approve the proposed amendments to the Articles (details of which are set out in the circular of the Company dated 18 April 2016), and that any Director be and is hereby authorised to modify the wordings of such amendments as appropriate (such amendments will not be required to be approved by the shareholders of the Company) and execute all such documents and/or do all such acts as the Directors may, in their absolute discretion, deem necessary or expedient and in the interest of the Company in order to deal with other related issues arising from the amendments to the Articles.	92,208,500 (100%)	0 (0%)	0 (0%)

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 8, these resolutions were duly passed as ordinary resolutions of the Company.

As more than two-thirds of the votes were cast in favour of each of the resolutions numbered 9 to 11, these resolutions were duly passed as special resolutions of the Company.

*Notes:*

1. As at the date of the AGM, the total number of issued Shares was 108,000,000 Shares, comprising 28,000,000 H Shares and 80,000,000 Domestic Shares, which represented the total number of shares entitling the holders to attend and vote on the proposed resolutions at the AGM.
2. There were no Shareholders, who, pursuant to Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), were required to abstain from voting in favour of any of the proposed resolutions at the AGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.
4. For the above resolutions, the Shareholders, proxies or authorised representatives holding in aggregate of 92,208,500 Shares, representing approximately 85.38% of the total voting Shares, were present in person or by proxy at the AGM.
5. The Company’s H share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

By order of the Board  
**Chuangmei Pharmaceutical Co., Ltd.\***  
**Yao Chuanglong**  
*Chairman*

Hong Kong, 3 June 2016

*As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan, Mr. Fan Jianbo and Mr. Lin Zhixiong; the non-executive director of the Company is Ms. You Zeyan; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).*

\* *For identification purposes only*